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Background: Insulin reduces platelet activation by inhibiting P2Y12 mediated signaling. However, platelets in patients with type 2 diabetes 
mellitus (T2DM) have reduced sensitivity to insulin, which results in upregulation of the P2Y12 pathway. This may contribute to their reduced 
responsiveness to the P2Y12 receptor antagonist clopidogrel. Therefore, it may be hypothesized that insulin sensitizing strategies may enhance 
clopidogrel-mediated P2Y12 inhibitory effects. The aim of this pilot pharmacodynamics (PD) study was to assess the impact of pioglitazone, a potent 
insulin sensitizer, on clopidogrel-mediated P2Y12 inhibitory effects in patients with T2DM.
Methods: This was a prospective, randomized, double-blind, placebo-controlled, cross-over PD study. Patients with T2DM and coronary artery 
disease on maintenance aspirin (81 mg/day) and clopidogrel (75 mg/day) were randomized to receive either pioglitazone 30 mg or matching 
placebo daily for 14 days. This was followed by a 2-week wash-out period, after which patients crossed-over therapy for 14 days. PD assessments 
were measured at four time points: baseline, 14 days after randomization, at the end of the wash-out period, and 14 days after cross-over. 
The primary endpoint measure was maximal platelet aggregation to 20 μM adenosine diphosphate (ADP) as assessed by light transmittance 
aggregometry (LTA). Flow cytometric analysis of vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) to determine P2Y12 reactivity index 
(PRI), and VerifyNow P2Y12 testing to determine platelet reaction units (PRU), were also performed.
Results: A total of 15 randomized patients completed the study and were available for analysis. Maximal platelet aggregation to 20 μM ADP 
(primary endpoint) was not significantly different with pioglitazone compared with placebo (49.53 ± 4.76 vs. 52.52 ± 3.89%; p = 0.594). Similarly, 
PRI (58.53 ± 7.15 vs. 59.18 ± 4.74; p = 0.935) and PRU (203.69 ± 22.97 vs. 240.58 ± 19.38; p = 0.117) did not differ significantly.
Conclusions: In patients with T2DM on maintenance aspirin and clopidogrel therapy, the adjunctive use of pioglitazone does not result in 
enhanced inhibition of platelet P2Y12 mediated signaling.
